Skip to main content

Compound Screening Assays

Assess therapeutic immunogenicity with optimized compound screening assays

Therapeutic lead optimization is a critical and challenging step in drug development that’s often a complex and time-consuming procedure when assessing primary immune cells.  

Our suite of primary immune cell screening ImmuSignature assays can screen compounds in an in-vitro simulated immune microenvironment, helping move hits into high-quality leads.  

These standardized assays have been specifically developed and validated to provide data from 4 weeks and feature:

  • Extensive primary immune cell QC
  • Statistically robust data sets
  • Multiple physiological readouts
  • HTRF® technology
  • Miniaturized semi-automated 3854 well platform 
Mixed Lymphocyte Reaction (MLR) assay

Rapidly identify agents that modulate APC-mediated T cell activation in high-throughput.

Learn more

T Cell Activation (TCA) assay

Isolate the effect of compounds that promote or block cell proliferation and T-cell activity.

Learn more

iTreg suppression assay

Efficiently identify therapeutic candidates that influence the suppression of T effector cells.

Learn more

iTreg polarization assay

Assess the impairment of T Lymphocyte regulatory cells and the effectiveness of therapeutic candidates.

Learn more

We’re here to help.

Contact us

Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.